Abstract
Background
Decreased cardiac metaiodobenzylguanidine (MIBG) uptake was reported in Parkinson’s disease and this contributes to the differential diagnosis between Parkinson’s disease and other forms of parkinsonism such as multiple system atrophy. However, decreased MIBG uptake of the thyroid has not been demonstrated.
Objective
To compare MIBG uptake of the thyroid among Parkinson’s disease, multiple system atrophy and controls.
Methods
Twenty-six patients with Parkinson’s disease, 11 patients with multiple system atrophy and 14 controls were examined in this study. Planar images were taken 15 minutes (early images) and 3 hours (late images) after intravenous injection of 111 MBq123I-MIBG.
Results
MIBG uptake of the thyroid on early images decreased significantly in Parkinson’s disease compared to controls (p < 0.0001) and multiple system atrophy (p = 0.018). MIBG uptake of the thyroid on early images decreased significantly also in multiple system atrophy compared to controls (p = 0.027). On late images, thyroid uptake differed significantly only between Parkinson’s disease and controls (p = 0.010).
Conclusions
Our study is the first to demonstrate decreased MIBG uptake of the thyroid in Parkinson’s disease. Sympathetic nervous denervation of Parkinson’s disease occurred not only in the heart but also in the thyroid.
Similar content being viewed by others
References
Hakusui S, Yasuda T, Yanagi T, Tohyama J, Hasegawa Y, Koike Y, et al. A radiological analysis of heart sympathetic functions with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure.J Auton Nerv Syst 1994;49:81–84.
Taki J, Nakajima K, Hwang EH, Matsunari I, Komai K, Yoshita M, et al. Peripheral sympathetic dysfunction in patients with Parkinson’s disease without autonomic failure is heart selective and disease specific.Eur J Nucl Med 2000; 27: 566–573.
Druschky A, Hilz MJ, Platsch G, Radespiel-Troger M, Druschky K, Kuweit T, et al. Differentiation of Parkinson’s disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT.J Neurol Sci 2000; 175: 3–12.
Reinhardt MJ, Jungling FD, Krause TM, Braune S. Scinti-graphic differentiation between two forms of primary dys-autonomia early after onset of autonomie dysfunction: value of cardiac and pulmonary iodine-123 MIBG uptake.Eur J Nucl Med 2000; 27: 595–600.
Orimo S. Usefulness of MIBG myocardial scintigraphy to differentiate parkinsonism and dementia with Lewy bodies.Neurol Med 2003; 58: 544–554. (in Japanese)
Taki J, Yoshita M, Yamada M, Tonami N. Significance of123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson’s disease and related disorders: it can be a specific marker for Lewy body disease.Ann Nucl Med 2004; 18: 453–461.
Goldstein DS, Holmes CS, Dendi R, Bruce SR, Li ST. Orthostatic hypotension from sympathetic denervation in Parkinson’s disease.Neurology 2002; 58: 1247–1255.
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinico-pathological study of 100 cases.J Neurol Neurosurg Psychiatry 1992; 55: 181–184.
Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, et al. Consensus statement on the diagnosis of multiple system atrophy.J Neurol Sci 1999; 163: 94–98.
Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality.Neurology 1967; 17: 427–442.
Goldstein DS, Holmes CS, Dendi R, Bruce SR, Li ST. Orthostatic hypotension from sympathetic denervation in Parkinson’s disease.Neurology 2002; 58: 1247–1255.
Yamamoto M.Parkinson ’s disease: Advances in pathology and autonomie nervous system. Tokyo; Chugai Igakusha 2004. (in Japanese)
Dae MW, De Marco T, Botvinick EH, O’Connell JW, Hattner RS, Huberty JP, et al. Scintigraphic assessment of MIBG uptake in globally denervated human and canine hearts—implications for clinical studies.J Nucl Med 1992; 33: 1444–1450.
Fagret D, Wolf JE, Vanzetto G, Borrel E. Myocardial uptake of metaiodobenzylguanidine in patients with left ventricular hypertrophy secondary to valvular aortic stenosis.J Nucl Med 1993; 34: 57–60.
Glowniak JV, Turner FE, Gray LL, Palac RT, Lagunas-Solar MC, Woodward WR. Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants.J Nucl Med 1989; 30: 1182–1191.
Sisson JC, Bolgos G, Johnson J. Measuring acute changes in adrenergic nerve activity of the heart in the living animal.Am Heart J 1991; 121: 1119–1123.
Jager WADH, Bethlem J. The distribution of Lewy bodies in the central and autonomic nervous system in idiopathic paralysis agitans.J Neurol Neurosurg Psychiatry 1960; 23: 283–290.
Nakajo M, Shimabukuro K, Yoshimura H, Yonekura R, Nakabeppu Y, Tanoue P, et al. Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart.J Nucl Med 1986; 27: 84–89.
Hirayama M, Kato R. The clinical assessment of peripheral sympathetic function using123I-metaiodobenzylguanidine.Neurol Med 1997; 47: 158–163.
Takahashi N, Inoue T, Oka T. Quantitative evaluation of cardiac disease using201Tl,99mTc-MIBI,123I-MIBG and123I-BMIPP single photon emission computed tomography.Jpn J Diag Imag 2002; 22: 749–759.
Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wieland DM, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man.J Nucl Med 1987; 28: 1625–1636.
Langston JW, Forno LS. The hypothalamus in Parkinson’s disease.Ann Neurol 1978; 3: 129–133.
Rajput AH, Rozdilsky B. Dysautonomia in parkinsonism. A clinicopathological study.J Neurol Neurosurg Psychiatry 1976; 39: 1092–1100.
Matthews MR. Autonomie ganglia in multiple system atrophy and pure autonomie failure. In: Bannister R, Mathias CJ (eds),Autonomie failure, 3rd ed. Oxford; Oxford University Press, 1992:593–621.
Chiueh CC, Zukowska-Grojec Z, Kirk KL, Kopin IJ. 6-Fluorocatecholamines as false adrenergic neurotransmitters.J Parmacol Exp Ther 1983; 225: 529–533.
Goldstein DS, Holmes C, Stuhlmuller JE, Lenders JW, Kopin IJ. 6-[18F]fluorodopamine positron emission tomographic scanning in the assessment of cardiac sympatho-neural function-studies in normal humans.Clin Auton Res 1997; 7: 17–29.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Matsui, H., Udaka, F., Oda, M. et al. Metaiodobenzylguanidine (MIBG) uptake in Parkinson’s disease also decreases at thyroid. Ann Nucl Med 19, 225–229 (2005). https://doi.org/10.1007/BF02984609
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02984609